(Q35630761)

9 August 2017

1 reference

title

Methotrexate and psoriasis in the era of new biologic agents (English)

1 reference

9 August 2017

1 reference

Frank C Saporito

1

1 reference

9 August 2017

M Alan Menter

series ordinal

2

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

Journal of the American Academy of Dermatology

9 August 2017

published in

1 reference

9 August 2017

volume

50

1 reference

9 August 2017

issue

2

1 reference

9 August 2017

page(s)

301-309

1 reference

Methotrexate in psoriasis: consensus conference

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

METHOTREXATE-INDUCED HEPATIC INJURY IN AN ADULT. A CASE REPORT

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Cirrhosis Associated With Methotrexate Treatment of Psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate and histologic hepatic abnormalities: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Use of methotrexate in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate therapy for psoriasis. Guideline revisions

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate guidelines--revised

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate in psoriasis: revised guidelines

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

An approach to the treatment of moderate to severe psoriasis with rotational therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Proceedings of the Psoriasis Combination and Rotation Therapy Conference. Deer Valley, Utah, Oct. 7-9, 1994

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate induced liver cirrhosis. Studies including serial liver biopsies during continued treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

The value of dynamic hepatic scintigraphy and serum aminoterminal propeptide of type III procollagen for early detection of methotrexate-induced hepatic damage in psoriasis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

The value of amino-terminal propeptide of type III procollagen in routine screening for methotrexate-induced liver fibrosis: a 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Outpatient liver biopsy: how safe is it?

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Outcome of patients hospitalized for complications after outpatient liver biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

A 21-year experience with major hemorrhage after percutaneous liver biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate-induced liver cirrhosis. A follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate-induced liver cirrhosis. Clinical, histological and serological studies--a further 10-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Low incidence of hepatotoxicity associated with long-term, low-dose oral methotrexate in treatment of refractory psoriasis, psoriatic arthritis, and rheumatoid arthritis. An acceptable risk/benefit ratio

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Sequential liver biopsies during long-term methotrexate treatment for psoriasis: a reappraisal

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate-induced cirrhosis requiring liver transplantation in three patients with psoriasis. A word of caution in light of the expanding use of this 'steroid-sparing' agent

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

T cell clones from psoriasis skin lesions can promote keratinocyte proliferation in vitro via secreted products

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Use of cyclosporin in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Tumor necrosis factor

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

An important role of tumor necrosis factor-alpha in the induction of adhesion molecules in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Administration of DAB389IL-2 to patients with recalcitrant psoriasis: a double-blind, phase II multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

A multicenter dose-escalation trial with denileukin diftitox (ONTAK, DAB(389)IL-2) in patients with severe psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Treatment with anti-tumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate inhibits the leukotriene B4 induced intraepidermal accumulation of polymorphonuclear leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Reduction of leukotriene B4-induced intraepidermal accumulation of polymorphonuclear leukocytes by methotrexate in psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate inhibits the human C5a-induced skin response in patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

The effect of methotrexate and hydroxyurea on neutrophil chemotaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Increased adenosine concentration in blood from ischemic myocardium by AICA riboside. Effects on flow, granulocytes, and injury

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Alteration of purine metabolism by AICA-riboside in human B lymphoblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Urinary adenosine and aminoimidazolecarboxamide excretion in methotrexate-treated patients with psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Adenosine: a physiological modulator of superoxide anion generation by human neutrophils.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Adenosine A2 receptor occupancy regulates stimulated neutrophil function via activation of a serine/threonine protein phosphatase

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

The antiinflammatory mechanism of methotrexate. Increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Inhibition of thymidine synthesis by folate analogues induces a Fas-Fas ligand-independent deletion of superantigen-reactive peripheral T cells

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. An open-label extension study

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Cyclosporine and methotrexate: a dangerous combination

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Cyclosporine consensus conference: with emphasis on the treatment of psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Combination treatment with methotrexate and cyclosporin for severe recalcitrant psoriasis

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

Successful treatment of severe recalcitrant psoriasis with combination infliximab and methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0190-9622%2803%2900803-X

7 January 2021

10.1016/S0190-9622(03)00803-X

Identifiers

DOI

1 reference

9 August 2017

1 reference